you’re right. Deferred is a big difference to rejection so the application is still up for consideration. They must have said yes to a lot of companies already. Like others, I would have thought since they are well established in the US they would be able to navigate that space with an advantage.
Ann: Deferral of FDA consideration of enforcement discretion, page-18
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.85 |
Change
0.060(0.88%) |
Mkt cap ! $4.908B | |||
| Open | High | Low | Value | Volume |
| $6.81 | $6.87 | $6.81 | $841.7K | 123.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 9407 | $6.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.86 | 5235 | 7 |
View Market Depth
| Last trade - 10.10am 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$6.93 |
Change
0.060 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $6.82 | $6.93 | $6.82 | 60544 | ||
| Last updated 10.28am 22/05/2024 ? | |||||
| A2M (ASX) Chart |